COVID-19 Project Team: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 13: Line 13:
'''Cardiovascular Disorders of COVID-19 Team Members'''
'''Cardiovascular Disorders of COVID-19 Team Members'''


*[[User:Behjat|Alieh Bahjat]]
*[[User:Behjat|Alieh Bahjat, M.D.]]
*'''[[User:Mandana Chitsazan|Mandana Chitsazan, M.D.]]'''
*'''[[User:Mandana Chitsazan|Mandana Chitsazan, M.D.]]'''
*'''[[User:Mitra Chitsazan|Mitra Chitsazan]]'''
*'''[[User:Mitra Chitsazan|Mitra Chitsazan, M.D.]]'''
*[[User:Mandana Safakhah|Mandana Safakhah]]
*[[User:Mandana Safakhah|Mandana Safakhah, M.D.]]
*[[User:Mounika|Mounika Vadiyala]]
*[[User:Mounika|Mounika Vadiyala, M.B.B.S.]]
*Sara Haddadi
*Sara Haddadi
*[[User:Sara Zand|Sara Zand]]
*[[User:Sara Zand|Sara Zand, M.D.]]
*[[User:Syed rizvi|Syed Rizvi]]
*[[User:Syed rizvi|Syed Rizvi, M.B.B.S.]]
*[[Tayyaba Ali, MD|Tayyaba Ali, M.D.]]
*[[Tayyaba Ali, MD|Tayyaba Ali, M.D.]]


Line 51: Line 51:
*'''[[User:Ramyar Ghandriz|Ramyar Ghandriz, M.D.]]'''
*'''[[User:Ramyar Ghandriz|Ramyar Ghandriz, M.D.]]'''
* [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]]
* [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]]
*[[User:ShakibaHassanzadeh|Shakiba Hassanzadeh]]
*[[User:ShakibaHassanzadeh|Shakiba Hassanzadeh, M.D.]]
*[[User:Fausatadogba|Fausat Adogba]]
*[[User:Fausatadogba|Fausat Adogba, M.D.]]


'''Nephrologic Disorders of COVID-19 Team Members'''
'''Nephrologic Disorders of COVID-19 Team Members'''
Line 64: Line 64:
*'''[[User:Syed Musadiq Ali|Syed Musadiq Ali, M.D.]]'''
*'''[[User:Syed Musadiq Ali|Syed Musadiq Ali, M.D.]]'''
*'''[[User:Niloofarsadaat Eshaghhosseiny|Niloofarsadaat Eshagh Hosseiny, M.D.]]'''
*'''[[User:Niloofarsadaat Eshaghhosseiny|Niloofarsadaat Eshagh Hosseiny, M.D.]]'''
*[[User:Muhammad Haider|Muhammad Adnan Haider]]
*[[User:Muhammad Haider|Muhammad Adnan Haider, M.B.B.S.]]
*[[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]]
*[[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]]
*[[User:Parul Pahal|Parul Pahal, M.B.B.S.]]
*[[User:Parul Pahal|Parul Pahal, M.B.B.S.]]
Line 74: Line 74:
'''Pulmonary Disorders and COVID-19 Team Members'''
'''Pulmonary Disorders and COVID-19 Team Members'''
*'''[[User:Sara Mohsin|Sara Mohsin, M.B.B.S.]]'''
*'''[[User:Sara Mohsin|Sara Mohsin, M.B.B.S.]]'''
* [[User:AFarheen|Ayesha Farheen Javid]]
* [[User:AFarheen|Ayesha Farheen Javid, M.B.B.S.]]
* [[User:Usmanaliakbar|Usman Ali Akbar]]
* [[User:Usmanaliakbar|Usman Ali Akbar, M.B.B.S.]]
*[[User:Rina Ghorpade|Rina Ghorpade]]
*[[User:Rina Ghorpade|Rina Ghorpade, M.B.B.S.]]
*Rana Aljebzi (not trained yet)
*Rana Aljebzi (not trained yet)

Revision as of 16:55, 17 June 2020

COVID-19 Project
Introduction
Team
Meetings' Summary
Topics
Ongoing Clinical Trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Meet The Team

Associate Editor(s)-in-Chief:

  • The name of the leaders are written in bold:

Cardiovascular Disorders of COVID-19 Team Members

Dermatologic Disorders of COVID-19 Team Members

Frequently Asked Inpatient Questions Team Members

Frequently Asked Outpatient Questions Team Members

Gastrointestinal disorders and of COVID-19

Hematologic disorders of COVID-19 Team Members

Nephrologic Disorders of COVID-19 Team Members

Neurologic Disorders and COVID-19 Team Members

Ongoing Clinical Trials of COVID-19 Team Members

Pediatrics and COVID-19

Pulmonary Disorders and COVID-19 Team Members